TITLE

Mucosal and systemic immune response against Neisseria meningitidis b induced by single time vaccination strategy

AUTHOR(S)
González, E.; Romeu, B.; Del Campo, J.; Acevedo, R.; Lastre, M.; Zayas, C.; Cuello, M.; Cabrera, O.; Balboa, J.; Nuñez, N.; Valdez, Y.; Fariñas, M.; Pérez, O.
PUB. DATE
May 2009
SOURCE
Revista VacciMonitor (Vacunología y Temas Afines);May-Aug2009, Vol. 18 Issue 2, p73
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Immunization is one of the most successful and cost-effective health interventions ever. Immunization have been helping to reduce child mortality, improving maternal health and combating infectious diseases. In spite of its, undisputed past success and promising future, however, immunization remains an unfinished agenda because of them inadequate coverage. Several factors have been largely responsible of a difficulty to attain immunization coverage and have been recognized as a problems of current vaccines, such as: the number of dose, excessive use of parenteral route, a small number of adjuvants approve for use in human, higher reactogenicity and unavailability against intracellular pathogens, infected or altered cells and scanty feasibility to combined more than one antigen in the same formulation. For bacterial meningitis WHO estimates that 1.2 million cases occur annually and Neisseria meningitidis is the etiological agent in more than 40% of these cases although some meningococcal vaccines are available. To bear in mind these principals problems, a novel protocol for vaccination against N. meningitidis called Single Time Vaccination Strategy (SinTimVaS) is proposed. Using female BALB/c mice, we induce systemic and mucosal immune responses against N. meningitidis with only one parenteral and one mucosal dose at the same time, employing the Finlay Adjuvants derivate from N. meningitidis, AFPL1 and AFCo1, respectively. In conclusion, SinTimVaS could increase the vaccination coverage and reduce the time-cost of vaccine campaigns, adding the possibility to increase the herd immunity by mucosal specific response induction.
ACCESSION #
40399200

 

Related Articles

  • Mucosal immune response induced by proteoliposome and cochleate derived from serogroups B N. meningitidis. Del Campo, Judith; Lastre, Miriam; Zayas, Caridad; Acevedo, Reinaldo; González, Elizabeth; Romeu, Belkis; Cuello, Maribel; Cabrera, Osmir; Balboa, Julio; Sarandi, Ali M.; Pérez, Oliver // Revista VacciMonitor (Vacunología y Temas Afines);May-Aug2009, Vol. 18 Issue 2, p69 

    Mucosal vaccination offers attractive advantages to conventional systemic vaccination. Most pathogens enter or establish infection at mucosal surfaces. This represents an enormous challenge for vaccine development. Nevertheless, the availability of safe and effective adjuvants that function...

  • Modulation of Immune Response to Group C Meningococcal Conjugate Vaccine Given Intranasally to Mice Together with the LTK63 Mucosal Adjuvant and the Trimethyl Chitosan Delivery System. Baudner, Barbara C.; Morandi, Maurizio; Giuliani, Marzia M.; J. Coos Verhoef; Junginger, Hans E.; Costantino, Paolo; Rappuoli, Rino; Del Giudice, Giuseppe // Journal of Infectious Diseases;3/1/2004, Vol. 189 Issue 5, p828 

    Previous work had shown that the immunogenicity of conjugate vaccine against group C meningococci (CRM-MenC) is enhanced when it is delivered intranasally (inl) with mucosal adjuvants, such as mutants of the Escherichia coli enterotoxin (LT), and with delivery systems such as chitosan ...

  • Construction of Opa-Positive and Opa-Negative Strains of Neisseria meningitidis to Evaluate a Novel Meningococcal Vaccine. Sadarangani, Manish; Claire Hoe, J.; Callaghan, Martin J.; Jones, Claire; Chan, Hannah; Makepeace, Katherine; Daniels-Treffandier, Hélène; Deadman, Mary E.; Bayliss, Christopher; Feavers, Ian; van der Ley, Peter; Pollard, Andrew J. // PLoS ONE;Dec2012, Vol. 7 Issue 12, p1 

    Neisseria meningitidis is a major global pathogen causing invasive disease with a mortality of 5-10%. Most disease in developed countries is caused by serogroup B infection, against which there is no universal vaccine. Opacity-associated adhesin (Opa) proteins are major meningococcal outer...

  • Nucleocapsid-like particles of dengue-2 virus enhance the immune response against a recombinant protein of dengue-4 virus. Lazo, Laura; Gil, Lázaro; Lopez, Carlos; Valdes, Iris; Marcos, Ernesto; Álvarez, Mayling; Blanco, Aracelys; Romero, Yaremis; Falcon, Viviana; Guzmán, María G.; Guillén, Gerardo; Hermida, Lisset // Archives of Virology;Oct2010, Vol. 155 Issue 10, p1587 

    In this study, we evaluate in mice a novel formulation containing nucleocapsid-like particles of dengue-2 virus (recNLP) co-immunized with a chimeric protein composed of the dengue-4 envelope domain III fused twice within the meningococcal P64k protein of Neisseria meningitidis (PD24). The...

  • Evidence of Positive Darwinian Selection in Putative Meningococcal Vaccine Antigens. Fitzpatrick, David; Creevey, Christopher; McInerney, James // Journal of Molecular Evolution;Jul2005, Vol. 61 Issue 1, p90 

    Meningococcal meningitidis is a life-threatening disease. In Europe and the United States the majority of cases are caused by virulent meningococcal strains belonging to serogroup B. Presently there is no effective vaccine against serogroup B strains, as traditional vaccine antigens such as...

  • Development of New Vaccines against Meningococcal Disease. Bröker, Michael // Drug Research / Arzneimittel-Forschung (Editio Cantor Verlag fur;Dec2003, Vol. 53 Issue 12, p805 

    Meningococcal diseases continue to have a major public health impact in many countries. Five major groups of Neisseria meningitidis (A, B, C, V and W135) are responsible for most meningococal diseases. Plain polysaccharides vaccines for Neisseria meningitidis groups A, C, V and W-135 have been...

  • Antibody persistence following MeNZB vaccination of adults and children and response to a fourth dose in toddlers. Jackson, Catherine; Lennon, Diana; Wong, Sharon; Yan, Jacqueline; Stewart, Joanna; Reid, Stewart; Oster, Philipp; Ypma, Ellen; Martin, Diana // Archives of Disease in Childhood;Aug2011, Vol. 96 Issue 8, p744 

    Background A New Zealand serogroup B meningococcal epidemic prompted trials of a strain-specific (B:4:P1.7-2,4) outer membrane vesicle vaccine (MeNZB). Methods Adults, school children, and infants provided serum after three MeNZB doses to evaluate antibody persistence via serum bactericidal...

  • Distinct Binding and Immunogenic Properties of the Gonococcal Homologue of Meningococcal Factor H Binding Protein. Jongerius, Ilse; Lavender, Hayley; Tan, Lionel; Ruivo, Nicola; Exley, Rachel M.; Caesar, Joseph J. E.; Lea, Susan M.; Johnson, Steven; Tang, Christoph M. // PLoS Pathogens;Aug2013, Vol. 9 Issue 8, p1 

    Neisseria meningitidis is a leading cause of sepsis and meningitis. The bacterium recruits factor H (fH), a negative regulator of the complement system, to its surface via fH binding protein (fHbp), providing a mechanism to avoid complement-mediated killing. fHbp is an important antigen that...

  • Optimizing the utilization of aluminum adjuvants in vaccines: you might just get what you want. HogenEsch, Harm; O'Hagan, Derek T.; Fox, Christopher B. // NPJ Vaccines;2018, Vol. 3 Issue 1, pN.PAG 

    Aluminum-containing adjuvants have been used for over 90 years to enhance the immune response to vaccines. Recent work has significantly advanced our understanding of the physical, chemical, and biological properties of these adjuvants, offering key insights on underlying mechanisms. Given the...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics